Related Experiment Videos
Clinical study of tetanus neonatorum
Indian Journal of Medical Sciences
|September 1, 1989
Summary
This study found that both tetanus-specific immune globulin (TIG) and anti-tetanus serum (ATS) had similar high mortality rates for neonatal tetanus. Ensuring vaccine potency through cold chain maintenance is crucial for maternal tetanus toxoid immunization.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Immunology
Background:
- Neonatal tetanus remains a significant cause of mortality in newborns.
- Predictive factors for poor prognosis include short incubation, low birth weight, fever, and tachycardia.
Purpose of the Study:
- To compare the efficacy of tetanus-specific immune globulin (TIG) versus anti-tetanus serum (ATS) in managing neonatal tetanus.
- To analyze mortality rates and identify factors influencing outcomes.
Main Methods:
- A comparative study of 76 neonatal tetanus cases, divided into two groups receiving TIG (46 cases) or ATS (30 cases).
- Standardized supportive therapies were administered to both groups.
- Mortality rates and corrected mortality due to tetanus per se were calculated.
Main Results:
- Overall mortality rates were high in both groups: 97.5% for TIG and 96.5% for ATS.
- Corrected mortality rates were 22.5% for TIG and 28.5% for ATS (p=0.5), indicating no significant difference.
- A notable percentage of infants were born to mothers with incomplete tetanus toxoid vaccination.
Conclusions:
- Tetanus-specific immune globulin (TIG) demonstrated no superiority over anti-tetanus serum (ATS) in treating moderate to severe neonatal tetanus.
- Emphasis on maintaining vaccine potency through proper cold chain management is vital for effective maternal immunization.
- Further research may be needed to explore alternative or adjunct therapies for improving neonatal tetanus outcomes.